Want to see SE:ELIC full AI Analyst Report?

Elicera Therapeutics AB (ELIC) Price & Analysis

3 Followers

ELIC Stock Chart & Stats

kr5.35

kr0.03(1.27%)

At close: Mar 06 4:00 PM EST

kr5.35

kr0.03(1.27%)

Day’s Range― - ―

52-Week Rangekr2.25 - kr8.21

Previous CloseN/A

Volume204.65K

Average Volume (3M)134.24K

Market Cap

kr159.50M

Enterprise Valuekr239.86

Total Cash (Recent Filing)kr17.86M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Aug 21, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding66,736,374

10 Day Avg. Volume92,396

30 Day Avg. Volume134,243

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.42

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetNo reported debt reduces refinancing and interest-rate risk, giving the company structural financial flexibility while it develops clinical programs. Over 2–6 months, this lowers default risk and supports funding options (equity or partnerships) to sustain R&D spend without immediate interest obligations.

High Gross Margin ProfileWhen products or services generate revenue the company shows very high gross margins, indicating scalable unit economics. If clinical candidates commercialize or generate partnering revenues, margin leverage can rapidly improve operating profitability versus peers with heavier COGS.

Specialized Immuno-oncology PipelineA focused pipeline in next-generation cell and gene therapies and persistence-enhancing CAR T technology represents a durable competitive moat in high unmet-need oncology niches. Platform differentiation can enable long-term partnerships, licensing, or targeted commercialization pathways.

Bears Say

Sustained Cash BurnMaterial negative operating and free cash flow at ~-27.8m TTM signals heavy ongoing funding needs. Over the next several months this raises dilution or financing risk, forcing capital raises or partner deals that can alter strategic priorities and ownership if revenue doesn't scale.

Very Low And Declining RevenueExtremely low and sharply declining revenue undermines operational sustainability and indicates limited commercial traction; with revenue near zero relative to burn, the firm cannot self-fund R&D. Over months this constraint elevates execution and commercialization risk absent new income sources.

Negative Returns And Eroding EquityA deeply negative ROE (~-57%) and declining equity reflect persistent losses and likely dilution. Structurally, this weakens the capital base and increases dependency on external funding, which can constrain strategic choices and dilute existing shareholders over the medium term.

ELIC FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was kr2.25 and its highest was kr8.21 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is kr159.50M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Aug 21, 2026 which is in 19 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Apr 21, 2026. The company reported -kr0.102 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -kr0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -32.414%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in SE:ELIC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.